EUVIMEDSkopri EUVIMED
FallberichtLeserbrief

Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98‐NSD1 +/ FLT3‐ITD + acute myeloid leukemia: A pediatric case report

Xiaojia Wen iD, Ying Wu, Pengli Huang, Huyong Zheng iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30308 ↗

At a glance

Fallbericht in Pediatric Blood & Cancer, 2023. Written by Xiaojia Wen and 3 co-authors. Institution: Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing, China. Major MEDLINE topics: Leukemia, Myeloid, Acute. Cited 8 times so far (Crossref); 5 references. Funded by: Natural Science Foundation of Beijing Municipality.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

To the Editor: In 2021, a 5-year-old male’s laboratory results showed a white blood cell count of 80 × 109/L, hemoglobin of 83 g/L, platelet count of 92 × 109/L, and 69% blast cells in peripheral blood. He was then diagnosed with acute myeloid leukemia (AML). Myeloid blast cells of bone marrow accounted for 81%, and morphological typing was M5. Bone marrow immunophenotyping indicated CD11b+, CD13 (dim), CD33+, CD34+, CD38+, CD64+, CD117+, CD123+, CD64+, MPO (dim), and HLA-DR+ myeloblasts, indicating development of AML. Bonemarrow karyotypewas normal with 46, XY.We tested 67 genetic mutations and 40 fusion genes common in myeloid blood disorders by PCR, including WT1, TET2, TP53, RUNX1, and KMT2A rearrangements. No other abnormalities were found except for FLT3-ITD. The FLT3-ITD mutation was detected with an insertion of ∼45 bp (∼70% mutation frequency), which was validated as a somatic mutation. Single-cell RNA sequencing showed a positive result for NUP98-NSD1, at 11.3765739:−5:176662822:+, which was classified as high risk. Extramedullary infiltration of leukemia was excluded. Thepatientwas enrolled in theChineseChildhoodLeukemiaGroupAML 2019 protocol multicenter study and first received induction chemotherapy with the DAH regimen (daunorubicin 40 mg/m2/day, cytarabine 200 mg/m2/day, and homoharringtonine 3 mg/m2/day). On Day 21 of induction therapy, his bone marrow suggested 5% blast cells, and flow cytometryminimal residual disease (FCM-MRD) was 9.89%, indicating a response to chemotherapy. However, the patient’s blast cells were elevated to 70%, and FCM-MRD was 66% on Day 28 of induction therapy, suggesting chemotherapy resistance and refractory AML. Then, the patient was treated with a combination of venetoclax 150 mg/m2/day, dasatinib 70 mg/m2/day, and low-dose chemotherapy including cytarabine 100 mg/m2/day and homoharringtonine 3 mg/m2/day as the second induction therapy of course II. Due to infection, dasatinib was only used for 2 days with venetoclax for 26 days. Fortunately, thepatient achieved complete remission (CR) onDay 21 of course II, and FCM-MRD, FLT3-ITD, and NUP98-NSD1 became negative on Day 28. The patient was then treated with a combination therapy of venetoclax 150 mg/m2/day, dasatinib 60 mg/m2/day, and azacitidine 75 mg/m2/day as consolidation therapy; both venetoclax and dasatinib were applied for 28 days, after which bonemarrowmor-

Subjects

MeSH terms (MEDLINE)

Leukemia, Myeloid, AcuteHumansChildDasatinibNuclear Pore Complex Proteinsfms-Like Tyrosine Kinase 3MutationHistone-Lysine N-MethyltransferaseSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Author keywords

FLT3 inhibitorsFLT3-ITDNUP98-NSD1acute myeloid leukemiadasatinibvenetoclax

Substances

DasatinibNuclear Pore Complex Proteinsfms-Like Tyrosine Kinase 3Histone-Lysine N-Methyltransferasenuclear pore complex protein 98venetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicFLT3 protein, humanNup98 protein, human

Authors and institutions

  • Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing, China.
  • National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
  • Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
  • Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

ORCID profiles: Xiaojia Wen, Huyong Zheng

Funding

  • Natural Science Foundation of Beijing Municipality

Cite

APA

Wen, X., Wu, Y., Huang, P., & Zheng, H. (2023). Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98‐NSD1 +/ FLT3‐ITD + acute myeloid leukemia: A pediatric case report. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30308

Vancouver

Wen X, Wu Y, Huang P, Zheng H. Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98‐NSD1 +/ FLT3‐ITD + acute myeloid leukemia: A pediatric case report. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30308

BibTeX
@article{Wen2023,
  author = {Wen, Xiaojia and Wu, Ying and Huang, Pengli and Zheng, Huyong},
  title = {Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98‐NSD1 +/ FLT3‐ITD + acute myeloid leukemia: A pediatric case report},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30308}
}
Start for free →